

10 October 2024

Osteopore strikes scaffold-based iPSC deal with US-based RxCell

Highlights

- Osteopore signs collaboration agreement with US-based induced pluripotent stem cells (iPSC) company RxCell Inc (RxCell).
- RxCell is a leading-edge iPSC company based in Utah, USA.
- RxCell President and CEO Dr Xianmin Zeng is a renowned stem cell biologist and neurobiologist with expertise in the development of PSC-based therapy and drug discovery.
- The agreement expands Osteopore into the scaffold-based cell therapy market, which is projected to surpass USD 4.39b by 2034.¹

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX; Osteopore or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the signing of a collaboration agreement between its subsidiary Osteopore International Pte Ltd and RxCell Inc (**RxCell**).

RxCell is a leading-edge biotechnology company dedicated to advancing the frontiers of therapeutic applications through induced pluripotent stem cells (iPSC).

¹ <https://www.precedenceresearch.com/scaffold-technology-market>

Combining the structural precision of scaffolds with the transformative power of cell therapy, this cutting-edge synergy pushes the boundaries of regenerative medicine, enabling Osteopore to pioneer life-changing solutions that speed up recovery and unlock the body's potential to regenerate, paving the way for improved patient outcomes.

RxCell is a leading biotechnology company focused on developing innovative cell therapies to treat degenerative diseases.

iPSC pioneer, RxCell President and CEO, Dr Xianmin Zeng focuses her research on neural development using iPSC to model neurodegenerative diseases. Dr Zeng was highlighted by the California Institute for Regenerative Medicine (CIRM) for her research into stem cells during her tenure as Professor at the Buck Institute for Research on Aging².

In 2012, the prominence of iPSCs grew significantly after Kyoto University Professor Shinya Yamanaka won the Nobel Prize.

Professor Yamanaka demonstrated that mature cells could be reprogrammed to become pluripotent, meaning they could transform into any cell type in the body, unlocking significant potential for targeted solutions. Since 2012, the development of iPSCs has progressed exponentially with a range of clinical studies commencing globally³.

Under the scope of the 18-month agreement, Osteopore and RxCell will set up a Technology Advisory Committee (TAC) comprising one nominee from each party to assess co-development and resource utilisation opportunities.

Subsequently, Osteopore and RxCell may seek third-party funding to support growth and development opportunities in scaffold-based cell therapy.

² <https://www.cirm.ca.gov/our-progress/video/parkinsons-ask-stem-cell-expert-xianmin-zeng-buck-institute/>

³ <https://www.nature.com/articles/s41392-024-01809-0>

Key highlights of the collaboration agreement:

- **Capabilities and expertise:** The collaboration will leverage Osteopore's proprietary scaffold-based technology and RxCell's cell-based therapeutic capabilities.
- **Joint development:** The parties will work together to co-design scaffold-based cellular products.
- **Clinical testing:** The collaboration will pave the way for pre-clinical studies to validate and progress the development of scaffold-based cellular products.
- **Commercialisation strategy:** Leveraging their networks and resources, the parties will collaborate on the commercialisation runway for scaffold-based cellular products.

Commenting on Osteopore's ground-breaking move into scaffold-based cell therapy, Executive Chairman Mark Leong, said:

"We are excited and actively exploring cutting-edge cellular therapies for tissue regeneration, each unlocking new possibilities for breakthrough healing.

"Combining our proven scaffold-based technology with cellular therapy is a game-changer—this powerful synergy will accelerate healing and drive full tissue regeneration. It's the future where the body doesn't just repair, it regenerates," said Mr Leong.

Commenting on the synergies created by the RxCell collaboration, Osteopore CEO Dr Yujing Lim said:

"Leveraging Osteopore's proven 3D-printed scaffold technology, our collaboration with RxCell signals our expansion into scaffold-based cell therapy. We are now looking towards the next stage of our synergy with cellular healing, where structure meets life.

"RxCell's leadership in iPSC therapy, combined with our scaffold technology, unlocks powerful synergies that have the potential to not only improve patient outcomes but change the game for regenerative medicine," said Dr Lim.

Commenting on the collaboration's potential to transform regenerative medicine, RxCell President & CEO Dr Xianmin Zeng, said:

"This collaboration is a key milestone for RxCell. Osteopore's proven track record in clinical development and commercialisation complements our capabilities in stem cell therapy.



For personal use only

“Together, we have the potential to advance the field of regenerative medicine and bring new, transformative therapies to patients worldwide,” said Dr Zeng.

In *The Future of Medtech in Australia*, RSM highlighted Osteopore’s ‘bright future as a regenerative medicine leader’. Osteopore is committed to broadening its collaboration with leading-edge businesses and expanding its presence in nascent markets to continue pushing the boundaries of regenerative medicine.

The agreement expands Osteopore’s business into the scaffold-based cell therapy market, which is expected to grow at a CAGR of 10% and surpass a projected market size of USD 4.39 billion by 2034⁴.

This announcement dated 10 October 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations

Purple

E: istewart@purple.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

⁴ <https://www.grandviewresearch.com/industry-analysis/scaffold-technology-market>

<https://www.alliedmarketresearch.com/scaffold-technology-market-A11103>

<https://www.futuremarketinsights.com/reports/scaffold-technology-market>

<https://www.precedenceresearch.com/scaffold-technology-market>

About RxCell

RxCell Inc., (RxCell) is a pioneering stem cell company based in Utah, USA, dedicated to advancing cellular therapeutics for age-related diseases including retinal degeneration. RxCell is at the forefront of cell therapy – particularly the therapeutic applications of induced pluripotent stem cells (iPSC).

With cutting-edge solutions such as their patented technology, RxCell is charting new territory in regenerative medicine. Additionally, RxCell markets cells and media as well as associated reagents for academic and drug discovery research via its subsidiary XCell Science.

<https://www.rxcellinc.com/>

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement.

The forward-looking statements in this announcement reflect views held only as of the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their advice before making any investment decision.